Bone tissue disorders arising from trauma or pathological issues pose a significant clinical burden worldwide, due to the growth and aging of the global population and the cost of associated medical interventions. The gold standard of surgical procedures for bone disease are bone grafts (autografts, allografts or xenografts) that consist in replacing the damaged tissue with a healthy one, explanted from the patient or from a donor. However, these treatments are restricted by the limited availability of bone and by infections that follow the harvesting of the tissue, as well as the risk of the graft rejection. In this context the Bone Tissue Engineering represent a possible alternative strategy, heading to the in vitro fabrication of viable engineered tissue substitutes, characterized by controlled mechanical, topographical, chemical and electrical properties.